Amnioreduction
Orphan DrugStandard of care
Description
Amnioreduction involves the removal of excess amniotic fluid in cases of polyhydramnios associated with twin-to-twin transfusion syndrome. While not curative, it provides symptomatic relief and may prolong pregnancy in mild cases or when laser therapy is not available. The procedure is performed under ultrasound guidance.
Indications & Therapeutic Use
Twin-to-twin transfusion syndrome, polyhydramnios, maternal respiratory compromise
Linked Diseases:
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Amnioreduction
| Generic Name | Amnioreduction |
| Active Ingredient | N/A - Procedural intervention |
| Drug Class | Twin-to-twin transfusion syndrome |
| Dosage Forms | Ultrasound-guided amniocentesis procedure |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Reg. Status | Standard of care |
| Clinical Trial | NCT00000000 |
| Countries | 8 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations9 Validated Nodes